anti-IL-8 monoclonal antibody

Anti-IL-8 monoclonal antibodies are a class of biologic therapies designed to neutralize Interleukin-8 (CXCL8), a pro-inflammatory chemokine that plays a multifaceted role in the tumor microenvironment (TME). IL-8 is a potent chemoattractant for neutrophils and myeloid-derived suppressor cells (MDSCs), which contribute to an immunosuppressive TME and facilitate tumor evasion from the immune system. Furthermore, IL-8 signaling promotes angiogenesis, epithelial-mesenchymal transition (EMT), and the maintenance of cancer stem cells. By binding to and neutralizing IL-8, these monoclonal antibodies aim to disrupt these pro-tumorigenic processes and enhance the activity of other immunotherapies, such as PD-1/PD-L1 inhibitors. Key clinical-stage candidates include BMS-986253 (formerly HuMax-IL8), developed by Bristol Myers Squibb, and AMY109, developed by Chugai Pharmaceutical. These agents are primarily being evaluated in Phase 1 and Phase 2 clinical trials for the treatment of advanced or metastatic solid tumors, including chordoma, colorectal cancer, and pancreatic cancer.

Other names

anti-IL-8 monoclonal antibodyanti-IL8 monoclonal antibodyanti-IL 8 monoclonal antibodyanti-CXCL8 monoclonal antibodyanti-CXCL-8 monoclonal antibodyanti-CXCL 8 monoclonal antibodyIL-8 neutralizing antibodyIL8 neutralizing antibodyIL 8 neutralizing antibodyinterleukin-8 inhibitorinterleukin8 inhibitorinterleukin 8 inhibitor